Latest news with #NasdaqHelsinki.Sign
Yahoo
02-05-2025
- Business
- Yahoo
301,521 Orion Corporation A shares converted into B shares
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE2 MAY 2025 at 9.00 EEST 301,521 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 301,521 A shares have been converted into 301,521 B shares. The conversion has been entered into the Trade Register on 2 May 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 32,450,742 A shares and 108,683,536 B shares. The number of votes of the company's shares is after the conversion 757,698,376. Orion Corporation René LindellCFO Olli HuotariEVP, Corporate Functions Contact person:Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq in to access your portfolio
Yahoo
24-04-2025
- Business
- Yahoo
Composition of the Nomination Committee of Orion Corporation
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE24 APRIL 2025 at 11.00 EEST Composition of the Nomination Committee of Orion Corporation The Board of Directors of Orion Corporation has appointed the following persons to the Nomination Committee of the company: Annika Ekman Petteri Karttunen Risto Karvonen Veli-Matti Mattila Hilpi Rautelin Seppo Salonen Hilpi Rautelin was appointed as Chair of the Committee. The duty of the committee is to prepare and present a recommendation to the Board of Directors for a proposal to the Annual General Meeting of shareholders concerning the composition and compensation of the Board. The essentials of the charter of the Nomination Committee and a description of the appointment process of its members are provided at a page in the Corporate Governance section of the Orion Group website. Orion Corporation Liisa HurmePresident and CEO Olli HuotariEVP, Corporate Functions Contact person:Olli Huotari, EVP, Corporate Functions, Secretary to the Board of Directors of Orion Corporation tel. +358 10 426 3054 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq in to access your portfolio
Yahoo
22-04-2025
- Business
- Yahoo
Invitation to Orion's Capital Markets Day on 22 May 2025
ORION CORPORATION INVESTOR NEWS 22 APRIL 2025 at 9.00 EEST Invitation to Orion's Capital Markets Day on 22 May 2025 Orion invites analysts, institutional investors, bankers and media representatives to its Capital Markets Day on Thursday 22 May 2025. The event will be held at Event Venue Eliel, at Töölönlahdenkatu 2, Helsinki, Finland. During the afternoon, Orion's President & CEO, Liisa Hurme, CFO René Lindell, and other members of the Executive Management Board will discuss Orion's growth strategy, financial objectives and businesses. Attendees will have the opportunity to ask questions during the event. Anyone can follow the event via a live webcast at starting at 13.00 EEST. The recording of the event will be available at the same address shortly after the event. The presentation materials will be available on Orion's website in the morning on 22 May 2025. The language of the event and the materials is English. Participants will have the opportunity to ask questions during the event. Questions can also be submitted via webcast. Agenda of Orion's Capital Markets Day 2025 12:45 EEST Registration 13:00 EEST The event and webcast begins 13:05 EEST Presentations Liisa Hurme, President and CEO Outi Vaarala, Executive Vice President, Innovative Medicines and Research & Development Hao Pan, Executive Vice President, Branded Products Q&ABREAK Satu Ahomäki, Executive Vice President, Generics and Consumer Health Niclas Lindstedt, Executive Vice President, Animal Health René Lindell, CFO Q&A 16:30 EEST Event ends The program is subject to change. A more detailed agenda will be available at: closer to the event. Registration In order to attend the event at the venue, please register at by 15 May 2025 at the latest. The number of seats is limited, and seats will be filled in order of registration. Contact person:Tuukka Hirvonen, Investor Relations, Orion Corporation tel. +358 10 426 2721 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq in to access your portfolio
Yahoo
09-04-2025
- Business
- Yahoo
Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025
ORION CORPORATION PRESS RELEASE 9 APRIL 2025 at 13.30 EEST Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025 Orion will publish Interim Report for January–March 2025 on Wednesday, 23 April 2025 at approximately 12.00 noon EEST. The release and related presentation material will be available on the company's website at after publishing. Webcast and conference call A webcast and a conference call for analysts, investors and media representatives will be held on Wednesday, 23 April 2025 at 13.30 EEST. A link to the live webcast is available on Orion's website at A recording of the event will be available on the website later the same day. Confenrence call can be joined by registering through the following link: Phone numbers and the conference ID to access the conference will be provided after the registration. In case you would like to ask a question during the conference, please dial *5 on your telephone keypad to enter the question queue. Questions can also be presented in writing through the question form of the webcast. Silent period The silent period preceding the publication is ongoing and continues until the disclosure. Contact person:Tuukka Hirvonen, Investor Relations, Orion Corporation tel. +358 10 426 2721 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq in to access your portfolio
Yahoo
11-03-2025
- Business
- Yahoo
Orion Corporation: Managers' transactions
ORION CORPORATION MANAGERS' TRANSACTIONS 11 MARCH 2025 at 09.00 EET Orion Corporation: Managers' transactions – Liisa Hurme Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Liisa HurmePosition: Chief Executive OfficerIssuer: Orion OyjLEI: 74370029VAHCXDR7B745Notification type: INITIAL NOTIFICATIONReference number: 99372/4/4 ____________________________________________Transaction date: 2025-03-10Outside a trading venueInstrument type: SHAREISIN: FI0009014377Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 17000 Unit price: 0 EUR Aggregated transactions (1): Volume: 17000 Volume weighted average price: 0 EUR Orion Corporation Liisa HurmePresident and CEO Olli HuotariExecutive Vice President, Corporate Functions Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp:// Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion's A and B shares are listed on Nasdaq in to access your portfolio
